Back to top
more

Clovis Oncology, Inc. (CLVS)

(Delayed Data from NSDQ)

$5.55 USD

5.55
7,328,936

-0.17 (0.04%)

Updated Mar 3, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum C VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (199 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down

Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.

Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.

Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug

Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.

Company News for Dec 22, 2020

Companies in the news are: LESL, RP, AJRD, CLVS

Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint

Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.

Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Clovis (CLVS) Up 18.6% Since Last Earnings Report: Can It Continue?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact

Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.

Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of 11.88% and -8.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaxo's Zejula Gets Positive CHMP View for First-Line Setting

The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.

Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Clovis (CLVS) Down 17.3% Since Last Earnings Report: Can It Rebound?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact

Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.

Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of -8.82% and -10.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis (CLVS) Upgraded to Buy: Here's Why

Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?

Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Clovis Completes Enrollment in Late-Stage Ovarian Cancer Study

Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.

Why Is Clovis (CLVS) Down 17.2% Since Last Earnings Report?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer

FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.

Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer

Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.

Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?

Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates

Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.

Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of 0.78% and 1.84%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?